Compare PDX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | TBPH |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.2M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | PDX | TBPH |
|---|---|---|
| Price | $21.43 | $18.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | N/A | ★ 496.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | N/A | ★ $80,327,000.00 |
| Revenue This Year | N/A | $70.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.47 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $13.52 | $7.90 |
| 52 Week High | $21.05 | $20.33 |
| Indicator | PDX | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 59.03 |
| Support Level | $21.39 | $17.25 |
| Resistance Level | $22.15 | $19.13 |
| Average True Range (ATR) | 0.34 | 0.66 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 56.35 | 85.64 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).